Placebo to match Tolebrutinib
Sponsors
Sanofi
Conditions
Non-relapsing Secondary Progressive Multiple SclerosisRelapsing Multiple Sclerosis
Phase 3
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
CompletedNCT04410991
Start: 2020-06-11End: 2024-07-16Updated: 2025-07-02
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
CompletedNCT04410978
Start: 2020-06-30End: 2024-07-15Updated: 2025-07-02
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
CompletedNCT04411641
Start: 2020-09-24End: 2024-08-29Updated: 2025-07-02